Real-world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study. (2021)

First Author: Milojkovic D
Attributed to:  Unravelling biological heterogeneity in neoplastic myeloproliferative stem cells funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1111/bjh.16733

PubMed Identifier: 32449159

Publication URI: http://europepmc.org/abstract/MED/32449159

Type: Journal Article/Review

Volume: 192

Parent Publication: British journal of haematology

Issue: 1

ISSN: 0007-1048